Tags

Type your tag names separated by a space and hit enter

Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential.
Cardiovasc Drug Rev. 2001 Summer; 19(2):152-71.CD

Abstract

Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential. Its major molecular targets recognized to date are membrane adrenoceptors (beta 1, beta 2, and alpha 1), reactive oxygen species, and ion channels (K+ and Ca2+). Carvedilol provides prominent hemodynamic benefits mainly through a balanced adrenoceptor blockade, which causes a reduction in cardiac work in association with peripheral vasodilation. This drug assures remarkable cardiovascular protection through its antiproliferative/atherogenic, antiischemic, antihypertrophic, and antiarrhythmic actions. These actions are a consequence of its potent antioxidant effects, amelioration of glucose/lipid metabolism, modulation of neurohumoral factors, and modulation of cardiac electrophysiologic properties. The usefulness of carvedilol in the treatment of hypertension, ischemic heart disease, and congestive heart failure is based on a combination of hemodynamic benefits and cardiovascular protection.

Authors+Show Affiliations

Department of Circulation, Research Institute of Environmental Medicine, Nagoya University, Furo-cho, Chikusa-ku, Nagoya 464-8601, Japan.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

11484068

Citation

Cheng, J, et al. "Carvedilol: Molecular and Cellular Basis for Its Multifaceted Therapeutic Potential." Cardiovascular Drug Reviews, vol. 19, no. 2, 2001, pp. 152-71.
Cheng J, Kamiya K, Kodama I. Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev. 2001;19(2):152-71.
Cheng, J., Kamiya, K., & Kodama, I. (2001). Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovascular Drug Reviews, 19(2), 152-71.
Cheng J, Kamiya K, Kodama I. Carvedilol: Molecular and Cellular Basis for Its Multifaceted Therapeutic Potential. Cardiovasc Drug Rev. 2001;19(2):152-71. PubMed PMID: 11484068.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. AU - Cheng,J, AU - Kamiya,K, AU - Kodama,I, PY - 2001/8/3/pubmed PY - 2002/1/5/medline PY - 2001/8/3/entrez SP - 152 EP - 71 JF - Cardiovascular drug reviews JO - Cardiovasc Drug Rev VL - 19 IS - 2 N2 - Carvedilol is a unique cardiovascular drug of multifaceted therapeutic potential. Its major molecular targets recognized to date are membrane adrenoceptors (beta 1, beta 2, and alpha 1), reactive oxygen species, and ion channels (K+ and Ca2+). Carvedilol provides prominent hemodynamic benefits mainly through a balanced adrenoceptor blockade, which causes a reduction in cardiac work in association with peripheral vasodilation. This drug assures remarkable cardiovascular protection through its antiproliferative/atherogenic, antiischemic, antihypertrophic, and antiarrhythmic actions. These actions are a consequence of its potent antioxidant effects, amelioration of glucose/lipid metabolism, modulation of neurohumoral factors, and modulation of cardiac electrophysiologic properties. The usefulness of carvedilol in the treatment of hypertension, ischemic heart disease, and congestive heart failure is based on a combination of hemodynamic benefits and cardiovascular protection. SN - 0897-5957 UR - https://www.unboundmedicine.com/medline/citation/11484068/Carvedilol:_molecular_and_cellular_basis_for_its_multifaceted_therapeutic_potential_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0897-5957&date=2001&volume=19&issue=2&spage=152 DB - PRIME DP - Unbound Medicine ER -